Chemotherapy for Participants With Lymphoma

Lymphoma, Large Cell, Diffuse Clinical Trial

Official title:
An Open-label, Single Arm, Phase 2 Study of Rituximab, Gemcitabine and Oxaliplatin Plus Enzastaurin as Treatment for Patients With Relapsed Diffuse Large B-Cell Lymphoma

Status Completed

Clinical Trial Summary

The primary purpose of this study is to help answer the following research questions:

- To assess whether Enzastaurin combined with rituximab, gemcitabine and oxaliplatin (R-GEMOX) can help participants with Diffuse Large B-Cell Lymphoma (DLBCL) remain free from disease and thus live longer.

- To assess for any side effects that might be associated with enzastaurin and R-GEMOX .

- To look at the characteristics and levels of certain genes and proteins to learn more about DLBCL and how enzastaurin works in the body.

- To look at the level of enzastaurin in the body and how long it remains.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00436280
Study type	Interventional
Source	Eli Lilly and Company
Contact
Status	Completed
Phase	Phase 2
Start date	February 2007
Completion date	November 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00532259` - CT-011 MAb in DLBCL Patients Following ASCT	Phase 2
Terminated	`NCT00322218` - Study Comparing Zevalin Regimen With no Further Treatment in Patients With Diffuse Large B-cell Lymphoma.	Phase 3
Completed	`NCT00689169` - Targeted Intensification With ZBEAM and Autologous Stem Cell Transplantation in Patients With High-grade B-Cell Lymphoma	Phase 2